Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Bladder cancer study results accepted for publication in Nature Communications

Hamlet Pharma is proud to announce that the report of the phase I/II bladder cancer trial has been accepted for publication in Nature Communications; a leading international journal.The paper is entitled "Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex" andhas been accepted for publication in Nature Communications. The Nature journals are extremely competitive and only accept innovative science of highest quality and with significant interest for a discerning audience. The journals are widely read, with a high impact. The paper analyses the structure of

GOBIO places orders for 100 Ironhand[®] systems

EUROPE TECHNOLOGIES' GOBIO has signed an agreement for purchasing 100 Ironhand[®] systems over a period of ten months. The order will secure the delivery of Ironhand systems to meet the high demand in the French market.[Ironhand Soft Active Exoskeleton] Bioservo and GOBIO have worked closely together since 2019 and have concluded many successful projects leading to an increasing demand from several industry segments. GOBIO is now able to commit on much larger quantities and putting in place an agreed delivery schedule will allow Bioservo to secure a more stable production level. “The

AFRY signs agreement to acquire Optima Nexus Consulting in Switzerland

The acquisition of Optima Nexus is in line with AFRY’s digitalisation strategy and will strengthen the capabilities within digital asset management.Optima Nexus is a Swiss-based digital company specialised in strategic asset management. The company has developed a digital asset management framework, Mobility Infrastructure Asset Management (MIAM), as well as a corresponding software suite to evaluate large asset portfolios. Optima Nexus focuses on advisory consulting in strategic asset management implementation of MIAM software suite, and support asset managers to evaluate the funding

Covid 19 prevention in public places and transports - Talkpool, Redytel, Netmore and Senseair form indoor air quality alliance

We are all concerned about the spread of Covid 19 in society - which to a large degree is transmitted by aerosols in the air we breathe. New technologies related to Internet of Things have allowed large scale deployment of sensors that are able to monitor air quality in real time. Based on positive initial results from pilot projects the parties have decided to form an indoor air quality alliance with the aim to provide solutions that can prevent the spread of Covid 19 and support a safe reopening of society. The relationship between CO2 levels and air quality has been documented for

Press invitation to Vattenfall’s Annual General Meeting 2021

The Annual General Meeting (AGM) of Vattenfall AB will take place on Wednesday 28 April at CEST 09.30. Due to the current situation the AGM can only be followed online at group.vattenfall.com/seThe AGM is held in Swedish and will be broadcast live on the web. A recorded version will be published later during the day at group.vattenfall.com/se In order to ask questions to the Vattenfall Board or Executive Directors of Vattenfall via telephone please call in 10-15 minutes before conference start: Sweden: +46 (0)8 5051 0031 UK: +44 (0) 207 107 06 13 In order to ask questions via

Diamyd Medical to present at Precision Medicine conference

CEO Ulf Hannelius has been invited to give a talk at the “Precision medicine – From patient to lab and back again” conference organized by the Copenhagen Bioscience Cluster, a Novo Nordisk foundation initiative.The talk, which is based on an abstract submitted to the conference entitled “Developing data-driven precision therapies for Type 1 diabetes”, will focus on how the data collected in Diamyd Medical’s clinical trials together with scientific advances in the field have informed the development of the precision medicine diabetes vaccine Diamyd[®] for the treatment of type 1 diabetes.

Bulletin from Scandic’s extraordinary general meeting

The extraordinary general meeting of Scandic was held on Wednesday April 21, 2021.  In order to mitigate the spread of Covid-19, the extraordinary general meeting was conducted by advance voting only, without physical presence of shareholders, proxies and third parties.The extraordinary general meeting resolved to approve the board of directors’ resolution on March 26, 2021, that the loan raised by Scandic at par value of not more than SEK 1,800,000,000 in total shall be convertible into shares in Scandic by way of an issue of convertible bonds. More information about the resolution is

World’s longest indoor autonomous vehicle test track now open

The automobile industry is undergoing change and tests and trials are being conducted more agilely. AstaZero is now opening the world’s longest indoor track for testing active safety systems and autonomous technologies for all types of vehicles. Vehicle operators are able to conduct tests 24 hours a day, 365 days a year, with reproducible light and surfaces. AstaZero is the world’s first full-scale independent testing and demonstration facility for future road safety, and it is now being expanded to house the world’s longest indoor track: 700 metres long and 40 metres wide.

DBP International: the feasibility studies for clinical site selection for Phase 1 SI-053 clinical trial is finalized - seven out of ten milestones for the clinical trial of SI-053 have been completed

Double Bond Pharmaceutical International AB (publ) (“DBP” or “Double Bond Pharmaceutical”) reports that the feasibility studies for clinical site selection for SI-053 Phase 1 clinical trial have been completed which resulted in the selection of four sites within the EU. This process of the feasibility studies has included: identify clinical investigators who are interested in participating in the trial, assessing site facilities, obtain input from investigators on trial design to align study procedures with clinical practice and support optimal patient recruitment, as well as to understand

Scandion Oncology engages former ASCO executive as clinical advisor

Scandion Oncology is pleased to announce that we have appointed Dr. Richard L. Schilsky, a seasoned and highly profiled international leader as a member of our clinical advisory board (CAB). Dr. Schilsky is the former CMO and Executive Vice President of the American Society of Clinical Oncology (ASCO) and a long-time faculty member of the University of Chicago.Copenhagen, April 21, 2021. Scandion Oncology, The Cancer Drug Resistance Company, is pleased to announce that Richard L. Schilsky, MD, FACP, FSCT, FASCO has accepted to join the clinical advisory board of Scandion Oncology. Dr.

VTT develops machine vision to support autonomous drones and robots – inspired by human vision system

Autonomously moving drones and other robots must observe their environment and interpret their observations without interruption. Using current technologies, this requires more energy than the batteries of a lightweight device can provide. That is why VTT and its partners are developing a fast, safe and energy-efficient machine vision system inspired by the human vision system.A machine vision system that observes the visible environment and interprets the observations made is the prerequisite for autonomous devices. To ensure speed and safety, the machine vision systems must use local

Employee Ownership Trust takes the wheel at F1 supplier

· Precision engineering services firm Retrac Productions is acquired by employees in an eight-figure deal. · New Employee Ownership Trust (EOT) secures multi-million-pound loan from Shawbrook Bank to support acquisition. · The move follows a growth in appetite for such schemes, with more than a quarter of the UK’s EOTs set up in 2019 alone*.PRESS RELEASE: 21st April 2021 A leading UK precision engineering firm has transferred ownership to an Employee Ownership Trust in an eight-figure deal as the business targets future growth, with support from Shawbrook Bank. Retrac Group’s

Fortum installs innovative battery solution at Landafors hydropower plant in Sweden

In development collaboration, Fortum, Volvo Cars, and Comsys have created an innovative battery solution that is now being installed at Fortum’s Landafors hydropower plant on the river Ljusnan in Sweden. The solution will also use batteries from plug-in hybrid cars and other batteries to extend the life of the hydropower turbines and the batteries themselves.   The purpose is to improve the ability to offer fast frequency reserve regulation to the power markets. The pilot also aims to find out how much capacity the batteries need to have left to function in this new “second life” role,

Catella publishes Annual Report 2020

The Catella AB (publ) Annual Report for 2020 have been published today and is available to download at www.catella.com.The English version will be available shortly. A printed version of the report can be ordered from:  Catella ABBox 5894102 40 StockholmPhone: +46 (0) 8 463 33 10info@catella.seThis information is information that Catella AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 11.00 CET on April 21 2021.

Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Asarina Pharma AB (publ) (“Asarina Pharma”) on 21 April 2021 in Stockholm. The CEO’s presentation is available at the company’s website.Adoption of income statement and balance sheet and discharge from liability The AGM resolved to adopt the income statement for the financial year 2020 as well as the balance sheet and consolidated balance sheet as of 31 December 2020. The members of the Board of Directors and the managing director were discharged from liability for the financial year 2020. Allocation of

Report from Nyfosa AB’s Annual General Meeting on April 21, 2021

Nyfosa AB’s Annual General Meeting was held today on Wednesday April 21, 2021. Due to the Covid-19 pandemic, the meeting was held only through advance postal voting pursuant to temporary legislation, and thus without the physical presence of shareholders, proxies or external parties. The main resolutions adopted were the following.Adoption of balance sheets and income statementsThe meeting resolved to adopt the balance sheet and the consolidated balance sheet as per December 31, 2020 as well as the income statement and the consolidated income statement for the financial year 2020.

Iron status in healthy pregnant women improved by the probiotic Probi FerroSorb® concept

Iron deficiency is the most common micronutrient deficiency and a global health problem. It is a very common challenge for women of childbearing age in general and especially for pregnant women. Therefore, many women start taking food supplements when they become pregnant. However, conventional high dose iron supplements commonly cause side effects like stomach pain and constipation. Thus, a more physiological approach for improving iron status is attractive when developing a new and safe product with clinical evidence. The previously reported study on improved iron status in healthy

Invitation to Presentation of Immunovia’s Interim Report January – March 2021

LUND (SWEDEN) – Immunovia will publish the company’s interim report for the period January 1 – March 31, 2021 on Wednesday, April 28, 2021 at 16:00 CET. Investors, analysts and media are invited to a telephone conference with web presentation on the same day at 16:30 CET. Patrik Dahlen, CEO, will present Immunovia and comment on the interim report followed by a Q&A session. The webcasted telephone conference will be held in English. To participate in the telephone conference, please call: Sweden: +46850558373  United Kingdom: +443333009267 United States: +18335268396

BioStock: Scandion Oncology’s COO previews key upcoming clinical milestones

Last month, Scandion Oncology took an important step in its transformation from early-stage biotech to a mature clinical stage company by appointing Maj Hedtjärn as new COO and Head of R&D operations. Hedtjärn is the latest addition to the company’s executive leadership team, and her extensive experience within R&D operations is an excellent fit for Scandion Oncology, which is aiming to build value as a clinical stage company. BioStock reached out to Hedtjärn to ask her about her role at Scandion Oncology and her vision at the company.Read the full interview with Maj Hedtjärn at biostock.se

Medicover’s Q1 report 2021 and invitation to a conference call

Medicover’s (MCOV B) Q1 report 2021 will be published on 29 April at 07.45 CEST. The Company will hold a conference call (in English) for media, financial analysts and investors at 09.30 CEST. CEO Fredrik Rågmark and CFO Joe Ryan will present the report and take questions. Shortly before the webcast, presentation slides will be available on medicover.com . To join the conference call please dial-in using the following details at least 10 minutes before the start of the call: Sweden: +46 (0) 856 618 467 UK: +44 (0) 2071 928

Mentice’s CEO Göran Malmberg to present the company’s interim report at a webcast conference call on April 28 at 9:30 CET

Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Elisabet Lund.To register for the presentation of the interim report for the period January – March 2021, which will be held on April 28 at 9.30 CET, visit www.mentice.com/financial-reports-presentations The presentation will be held in English. Participants are advised to register at least a few minutes in advance.

Nanologica Announces Date Change for Annual Report

Nanologica AB (publ) has changed the previously disclosed publication date of April 23, 2021 for the company’s annual report 2020 to May 5, 2021.Financial calendar 2021 Interim report January-March 2021                         April 23, 2021 Annual Report 2020                                                  May 5, 2021 Interim report January-June 2021                             July 9, 2021 Interim report January-September 2021           October 29, 2021 For further information, please contact: Johanna Johansson, IR NanologicaPh: +46 72 211 21 90 or e-mail: johanna.

There are no items matching the current filter
There are no more items matching the current filter
Back to top